PMID- 21854084
OWN - NLM
STAT- MEDLINE
DCOM- 20120525
LR  - 20211020
IS  - 1029-2403 (Electronic)
IS  - 1042-8194 (Print)
IS  - 1026-8022 (Linking)
VI  - 53
IP  - 2
DP  - 2012 Feb
TI  - Mechanisms regulating enhanced human leukocyte antigen class II-mediated CD4 + T 
      cell recognition of human B-cell lymphoma by resveratrol.
PG  - 305-14
LID - 10.3109/10428194.2011.615423 [doi]
AB  - Malignant B-cells express measurable levels of human leukocyte antigen (HLA) 
      class II proteins, but often escape immune recognition by CD4 + T cells. 
      Resveratrol (Resv) has been the focus of numerous investigations due to its 
      potential chemopreventive and anti-cancer effects, but it has never been tested 
      in the regulation of immune components in B-cell tumors. Here, we show for the 
      first time that Resv treatment enhances HLA class II-mediated immune detection of 
      B-cell lymphomas by altering immune components and class II presentation in tumor 
      cells. Resv treatment induced an up-regulation of both classical and 
      non-classical HLA class II proteins (DR and DM) in B-lymphoma cells. Resv also 
      altered endolysosomal cathepsins (Cat S, B and D) and a thiol reductase (GILT), 
      increasing HLA class II-mediated antigen (Ag) processing in B-cell lymphomas and 
      their subsequent recognition by CD4 + T cells. Mechanistic study demonstrated 
      that Resv treatment activated the recycling class II pathway of Ag presentation 
      through up-regulation of Rab 4B protein expression in B-lymphoma cells. These 
      findings suggest that HLA class II-mediated immune recognition of malignant 
      B-cells can be improved by Resv treatment, thus encouraging its potential use in 
      chemoimmunotherapy of B-cell lymphoma.
FAU - Radwan, Faisal F Y
AU  - Radwan FF
AD  - Department of Microbiology and Immunology, Hollings Cancer Center and Children's 
      Research Institute, Medical University of South Carolina, Charleston, SC 29425, 
      USA.
FAU - Zhang, Lixia
AU  - Zhang L
FAU - Hossain, Azim
AU  - Hossain A
FAU - Doonan, Bently P
AU  - Doonan BP
FAU - God, Jason M
AU  - God JM
FAU - Haque, Azizul
AU  - Haque A
LA  - eng
GR  - P30 CA138313/CA/NCI NIH HHS/United States
GR  - R01 CA129560/CA/NCI NIH HHS/United States
GR  - CA129560/CA/NCI NIH HHS/United States
GR  - CA129560-S1/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20111024
PL  - United States
TA  - Leuk Lymphoma
JT  - Leukemia & lymphoma
JID - 9007422
RN  - 0 (Antineoplastic Agents, Phytogenic)
RN  - 0 (HLA-D Antigens)
RN  - 0 (Stilbenes)
RN  - EC 3.4.- (Cathepsins)
RN  - Q369O8926L (Resveratrol)
SB  - IM
MH  - Antigen Presentation
MH  - Antineoplastic Agents, Phytogenic/*pharmacology
MH  - Blotting, Western
MH  - CD4-Positive T-Lymphocytes/*immunology
MH  - Cathepsins/metabolism
MH  - Cell Proliferation
MH  - Endocytosis
MH  - Flow Cytometry
MH  - HLA-D Antigens/immunology/*metabolism
MH  - Humans
MH  - Lymphoma, B-Cell/*drug therapy/*immunology/metabolism
MH  - Resveratrol
MH  - Stilbenes/*pharmacology
MH  - Tumor Cells, Cultured
PMC - PMC4287222
MID - NIHMS439627
COIS- Conflicts of Interest The authors have no financial conflicts of interest.
EDAT- 2011/08/23 06:00
MHDA- 2012/05/26 06:00
PMCR- 2015/01/08
CRDT- 2011/08/23 06:00
PHST- 2011/08/23 06:00 [entrez]
PHST- 2011/08/23 06:00 [pubmed]
PHST- 2012/05/26 06:00 [medline]
PHST- 2015/01/08 00:00 [pmc-release]
AID - 10.3109/10428194.2011.615423 [doi]
PST - ppublish
SO  - Leuk Lymphoma. 2012 Feb;53(2):305-14. doi: 10.3109/10428194.2011.615423. Epub 
      2011 Oct 24.